Gilead’s Remdesivir Reportedly Flopped in Chinese COVID-19 Study
Gilead's Remdesivir Reportedly Flopped in Chinese COVID-19 Study 1Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights Gilead Sciences’ (NASDAQ:GILD) experimental antiviral drug …
News story posted on 2020-04-24T00:45:00.0000000Z